Literature DB >> 15036328

Subclinical cardiac involvement in myotonic dystrophy manifesting as decreased myocardial Doppler velocities.

Dragos Vinereanu1, Balwinder P S Bajaj, Jane Fenton-May, Mark T Rogers, Christoph F Mädler, Alan G Fraser.   

Abstract

To assess subendocardial (long-axis) and mid-wall (short-axis) left ventricular (LV) function in patients with type 1 myotonic dystrophy (MD1), with no symptoms or clinical signs of heart disease, to investigate if they have subclinical cardiac involvement, 28 subjects (14 with MD1, and 14 age- and sex-matched normals) had conventional and tissue Doppler echocardiography. Myocardial velocities and timings to peak systolic contractions were measured. LV wall thickness, diameters, and ejection fraction were not different between the groups. 4/14 of the MD1 patients (29%) had global diastolic dysfunction. Both long-axis and short-axis systolic and early diastolic myocardial velocities were lower in patients with MD1, whereas time-to-peak myocardial contraction was longer; mean longitudinal systolic velocity was 5.5+/-1.7 cm/s in patients with MD1, compared with 7.8+/-1.3 cm/s in normal subjects (P<0.001) 10/14 of the patients (71%) had reduced longitudinal systolic function. Longitudinal systolic and diastolic velocities were inversely related to the duration of the QRS complex ( r=-0.86 and r=-0.63 respectively, both P<0.01), but they did not correlate with the CTG-repeat size. Patients with MD1 have subclinical cardiac impairment revealed by measurement of myocardial velocities using tissue Doppler echocardiography.

Entities:  

Mesh:

Year:  2004        PMID: 15036328     DOI: 10.1016/j.nmd.2003.11.005

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  6 in total

1.  Elevation of RNA-binding protein CUGBP1 is an early event in an inducible heart-specific mouse model of myotonic dystrophy.

Authors:  Guey-Shin Wang; Debra L Kearney; Mariella De Biasi; George Taffet; Thomas A Cooper
Journal:  J Clin Invest       Date:  2007-10       Impact factor: 14.808

2.  Pentamidine rescues contractility and rhythmicity in a Drosophila model of myotonic dystrophy heart dysfunction.

Authors:  Mouli Chakraborty; Estela Selma-Soriano; Emile Magny; Juan Pablo Couso; Manuel Pérez-Alonso; Nicolas Charlet-Berguerand; Ruben Artero; Beatriz Llamusi
Journal:  Dis Model Mech       Date:  2015-10-29       Impact factor: 5.758

Review 3.  Cardiac Pathology in Myotonic Dystrophy Type 1.

Authors:  Mani S Mahadevan; Ramesh S Yadava; Mahua Mandal
Journal:  Int J Mol Sci       Date:  2021-11-02       Impact factor: 5.923

4.  Mice lacking MBNL1 and MBNL2 exhibit sudden cardiac death and molecular signatures recapitulating myotonic dystrophy.

Authors:  Kuang-Yung Lee; Carol Seah; Ching Li; Yu-Fu Chen; Chwen-Yu Chen; Ching-I Wu; Po-Cheng Liao; Yu-Chiau Shyu; Hailey R Olafson; Kendra K McKee; Eric T Wang; Chi-Hsiao Yeh; Chao-Hung Wang
Journal:  Hum Mol Genet       Date:  2022-09-10       Impact factor: 5.121

5.  Right atrial preference pacing algorithm in the prevention of paroxysmal atrial fibrillation in myotonic dystrophy type 1 patients: a long term follow-up study.

Authors:  Gerardo Nigro; Vincenzo Russo; Anna Rago; Andrea Antonio Papa; Alberto Palladino; Luisa Politano
Journal:  Acta Myol       Date:  2012-10

6.  Structural myocardial involvement in adult patients with type 1 myotonic dystrophy.

Authors:  Upinder K Dhand; Faisal Raja; Kul Aggarwal
Journal:  Neurol Int       Date:  2013-03-21
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.